CML and the WHO: Why?

By sjmartinez • December 13, 2023

Berman E, Shah NP, Deninger M, Altman JK, Amaya M, Begna K, Bhatia R, Chan O, Collins R, Curtin P, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore J, Oehler V, Pratz K, Pusic I, Rose M, Shomali W, Smith BD, Styler M, Sweet K, Talpaz M, Tanaka T, Tantravahi S, Tsai S, Vaughn J, Welborn J, Yang D, Mauro M, Cortes J, Radich J, Druker B. CML and the WHO: Why? J Clin Oncol. 2023 Dec 12:JCO2301689. doi: 10.1200/JCO.23.01689. Epub ahead of print. PMID: 38086008.

Tags: Hematology/Oncology, Publications

Related Posts

Dose-escalated stereotactic body radiotherapy re-irradiation in patients with recurrent head and neck cancer: a prospective phase 2 study using automated non-coplanar volumetric modulated arc therapy

Nikitas J, Ma TM, Cook K, Woods K, Kishan AU, Reddy VK, Hegde JV, John MS, Chai-Ho W, Wong D, Chu FI, Felix C, Tenn[...]

Stereotactic Body Radiation Therapy Utilization Trends for Stage I Non-Small Cell Lung Cancer

Sakowitz S, Tupper HI, Benjamin LN, Oh S, He T, Ronaghi R, Channick CL, Rosenberg BJ, Salehi-Rad R, Smith MI, Bando JM, Young TJ, Barjaktarvic[...]

Liquid Biopsy of Circulating Tumor Cells and DNA in the Context of PSMA Radiopharmaceutical Therapy

Holzgreve A, Mona CE, Kimura K, Li X, Zhu Y, Tseng HR, Lee JK, Drakaki A, Garraway IP, Rettig MB, Calais J, Salavati A. Liquid[...]